BioNexus Gene Lab Corp. Proceeds from Issuance or Sale of Equity
BioNexus Gene Lab Corp. (BGLC) reported Proceeds from Issuance or Sale of Equity of $267.31 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2026-04-14
- BioNexus Gene Lab Corp. proceeds from issuance or sale of equity for fiscal 2025 was $267.31K.
| Period end | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|
| 2025-12-31 | $267.31K 10-K · filed 2026-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |